Hürthle Cell Carcinoma

Open Access
Publisher Website
Google Scholar
Abstract
Background: Hürthle cell carcinoma represents approximately 3% of all differentiated thyroid cancers. The terminology is often confusing, and discrimination between Hürthle cell carcinoma and benign Hürthle cell tumors can be unclear. Thus, optimal treatment of patients with these diseases remains unsettled. Methods: The authors reviewed published evidence on the presentation, biologic behavior, and treatment outcomes for this disease. In addition, they summarized their experience involving a series of 14 patients with Hürthle cell carcinoma. Results: Hürthle cell carcinoma generally produces thyroglobulin and rarely takes up radioactive iodine. It is frequently bilateral or multifocal within the thyroid gland and often presents with local invasion. Hürthle cell carcinoma is associated with a high rate of locoregional recurrence and significant mortality. Conclusions: The authors advocate total thyroidectomy with central neck dissection as the therapy of choice for patients with Hürthle cell carcinoma.